The U.S. flu season is starting slowly, and it’s not clear if it will be as bad as last winter’s. But some health experts are ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

Vaccine mismatches may raise severity risks this flu season. Low vaccination uptake increases overall flu transmission ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Flu vaccines are crucial tools in protecting public health by reducing the risk of influenza illness and its complications.

The Infectious Diseases Society of America updates flu and RSV vaccine guidelines, emphasizing safety for immunocompromised patients during respiratory virus season. The Infectious Diseases Society of ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...

Study shows high-dose vaccines work better for older adults while cell-based versions benefit younger people as respiratory ...

Connecticut confirmed the state’s first flu death of the season on Thursday. It was a person in their 80s from Hartford ...